Autonomous Therapeutics, Inc.
Autonomous Therapeutics is pioneering new classes of nucleic acids to develop first-in-class medicines that are target-activated and variant-proof, aiming to end viral pandemics and treat metastatic cancers. The company is focused on encrypted RNA technology and has received funding from DARPA, NIH, BARDA, and other notable investors. It is committed to developing next-generation antivirals and therapeutics with a mission to create precision, resistance-proof immunity and innovative treatments.
Industries
Nr. of Employees
small (1-50)
Autonomous Therapeutics, Inc.
Products
Platform for variant-resistant nucleic acid therapeutics
A platform approach to design nucleic acid therapeutics that are target-activated and engineered for broad efficacy across viral variants, intended for prophylactic and therapeutic applications including respiratory delivery options.
Platform for variant-resistant nucleic acid therapeutics
A platform approach to design nucleic acid therapeutics that are target-activated and engineered for broad efficacy across viral variants, intended for prophylactic and therapeutic applications including respiratory delivery options.
Services
Collaborative research agreements and program partnerships with government agencies and industry to develop nucleic acid-based countermeasures and therapeutics.
End-to-end preclinical discovery services including protein engineering, nucleic acid optimization, LNP formulation, cell-based assay development, and automated high-throughput screening.
Collaborative research agreements and program partnerships with government agencies and industry to develop nucleic acid-based countermeasures and therapeutics.
End-to-end preclinical discovery services including protein engineering, nucleic acid optimization, LNP formulation, cell-based assay development, and automated high-throughput screening.
Expertise Areas
- RNA therapeutics
- Antiviral drug discovery
- Synthetic biology
- Protein engineering
Key Technologies
- Target-activated nucleic acid therapeutic platforms
- Lipid nanoparticle (LNP) delivery
- High-throughput automated screening and lab robotics
- Protein design using molecular dynamics and AI
News & Updates
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
Autonomous Therapeutics received a $1 million award from BARDA and Johnson & Johnson Innovation to develop a prophylactic providing protection against all variants of SARS-CoV-2.
DARPA supports PREventing EMerging Pathogenic Threats (PREEMPT) initiative
DARPA selected Autonomous Therapeutics to support a 3.5-year program to contain viral diseases in animal reservoirs and insect vectors.
Autonomous selected for BLUE KNIGHT initiative
Autonomous was chosen for a joint initiative between BARDA and JLABS to stimulate innovation in health security.
Autonomous Therapeutics collaborates with Mink Therapeutics
The collaboration aims to develop therapies targeting metastatic tumors using encrypted RNA and iNKT cell therapies.
Autonomous CEO Dr. Ariel Weinberger presents at NIH and World Congresses
Dr. Weinberger has presented on encrypted RNA technology, pandemic preparedness, and novel mRNA therapeutics at various conferences.
Ariel Weinberger discusses resistance-proof RNA platform technologies and their potential to combat mutating viral threats.
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
Autonomous Therapeutics received a $1 million award from BARDA and Johnson & Johnson Innovation to develop a prophylactic providing protection against all variants of SARS-CoV-2.
DARPA supports PREventing EMerging Pathogenic Threats (PREEMPT) initiative
DARPA selected Autonomous Therapeutics to support a 3.5-year program to contain viral diseases in animal reservoirs and insect vectors.
Autonomous selected for BLUE KNIGHT initiative
Autonomous was chosen for a joint initiative between BARDA and JLABS to stimulate innovation in health security.
Autonomous Therapeutics collaborates with Mink Therapeutics
The collaboration aims to develop therapies targeting metastatic tumors using encrypted RNA and iNKT cell therapies.
Autonomous CEO Dr. Ariel Weinberger presents at NIH and World Congresses
Dr. Weinberger has presented on encrypted RNA technology, pandemic preparedness, and novel mRNA therapeutics at various conferences.
Ariel Weinberger discusses resistance-proof RNA platform technologies and their potential to combat mutating viral threats.